Literature DB >> 20956813

Ductal carcinoma in situ: risk factors and impact of screening.

Beth A Virnig1, Shi-Yi Wang, Tatyana Shamilyan, Robert L Kane, Todd M Tuttle.   

Abstract

BACKGROUND: The National Institutes of Health Office of Medical Applications of Research commissioned a structured literature review on the incidence of ductal carcinoma in situ (DCIS) as a background paper for the State of the Science Conference on Diagnosis and Management of DCIS.
METHODS: Published studies were abstracted from MEDLINE and other sources. We include articles published through January 31, 2009; 92 publications were abstracted.
RESULTS: DCIS incidence rose from 1.87 per 100,000 in 1973-1975 to 32.5 per 100,000 in 2005. Increases in incidence were greatest in tumors without comedo necrosis. Incidence increased in all ages but more in women older than 50 years. Increased use of mammography explains some but not all of the increased incidence. Risk factors for incident DCIS include older age and positive family history. Whereas tamoxifen prevents both invasive breast cancer and DCIS, raloxifene is associated with decreased invasive breast cancer but not decreased DCIS.
CONCLUSIONS: Scientific questions deserving further investigation include the relationship between mammography use and DCIS incidence and the role of chemoprevention for reducing the incidence of DCIS and invasive breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956813      PMCID: PMC5161075          DOI: 10.1093/jncimonographs/lgq024

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  33 in total

1.  The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up.

Authors:  L Tabár; B Vitak; H H Chen; S W Duffy; M F Yen; C F Chiang; U B Krusemo; T Tot; R A Smith
Journal:  Radiol Clin North Am       Date:  2000-07       Impact factor: 2.303

2.  Recent trends and racial/ethnic differences in the incidence and treatment of ductal carcinoma in situ of the breast in California women.

Authors:  Kaire Innos; Pamela L Horn-Ross
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

3.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

4.  Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001.

Authors:  Christopher I Li; Janet R Daling; Kathleen E Malone
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-04       Impact factor: 4.254

5.  Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer.

Authors:  K Kerlikowske; J Barclay; D Grady; E A Sickles; V Ernster
Journal:  J Natl Cancer Inst       Date:  1997-01-01       Impact factor: 13.506

6.  Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Authors:  Silvana Martino; Jane A Cauley; Elizabeth Barrett-Connor; Trevor J Powles; John Mershon; Damon Disch; Roberta J Secrest; Steven R Cummings
Journal:  J Natl Cancer Inst       Date:  2004-12-01       Impact factor: 13.506

7.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

Authors:  J Cuzick; J Forbes; R Edwards; M Baum; S Cawthorn; A Coates; A Hamed; A Howell; T Powles
Journal:  Lancet       Date:  2002-09-14       Impact factor: 79.321

8.  Oral contraceptives and the risk of ductal breast carcinoma in situ.

Authors:  Elizabeth B Claus; Meredith Stowe; Darryl Carter
Journal:  Breast Cancer Res Treat       Date:  2003-09       Impact factor: 4.872

9.  Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer.

Authors:  Stephen W Duffy; Olorunsola Agbaje; Laszlo Tabar; Bedrich Vitak; Nils Bjurstam; Lena Björneld; Jonathan P Myles; Jane Warwick
Journal:  Breast Cancer Res       Date:  2005-11-10       Impact factor: 6.466

10.  The association of mammographic density with ductal carcinoma in situ of the breast: the Multiethnic Cohort.

Authors:  Jasmeet K Gill; Gertraud Maskarinec; Ian Pagano; Laurence N Kolonel
Journal:  Breast Cancer Res       Date:  2006-06-23       Impact factor: 6.466

View more
  24 in total

1.  Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study.

Authors:  Maeve Mullooly; Zeina G Khodr; Cher M Dallal; Sarah J Nyante; Mark E Sherman; Roni Falk; Linda M Liao; Jeffrey Love; Louise A Brinton; Gretchen L Gierach
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

2.  BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression.

Authors:  Hanan S Elsarraj; Yan Hong; Darlene Limback; Ruonan Zhao; Jenna Berger; Stephanie C Bishop; Aria Sabbagh; Linzi Oppenheimer; Haleigh E Harper; Anna Tsimelzon; Shixia Huang; Susan G Hilsenbeck; Dean P Edwards; Joseph Fontes; Fang Fan; Rashna Madan; Ben Fangman; Ashley Ellis; Ossama Tawfik; Diane L Persons; Timothy Fields; Andrew K Godwin; Christy R Hagan; Katherine Swenson-Fields; Cristian Coarfa; Jeffrey Thompson; Fariba Behbod
Journal:  NPJ Breast Cancer       Date:  2020-04-24

Review 3.  Current management of lesions associated with an increased risk of breast cancer.

Authors:  Monica Morrow; Stuart J Schnitt; Larry Norton
Journal:  Nat Rev Clin Oncol       Date:  2015-01-27       Impact factor: 66.675

4.  Comparative Effectiveness of Surgical Options for Patients with Ductal Carcinoma In Situ: An Instrumental Variable Approach.

Authors:  Lewei Duan; Aniket A Kawatkar
Journal:  Perm J       Date:  2018

5.  Screening Mammography Outcomes: Risk of Breast Cancer and Mortality by Comorbidity Score and Age.

Authors:  Joshua Demb; Linn Abraham; Diana L Miglioretti; Brian L Sprague; Ellen S O'Meara; Shailesh Advani; Louise M Henderson; Tracy Onega; Diana S M Buist; John T Schousboe; Louise C Walter; Karla Kerlikowske; Dejana Braithwaite
Journal:  J Natl Cancer Inst       Date:  2020-06-01       Impact factor: 13.506

Review 6.  The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ.

Authors:  Robert L Kane; Beth A Virnig; Tatyana Shamliyan; Shi-Yi Wang; Todd M Tuttle; Timothy J Wilt
Journal:  J Natl Cancer Inst Monogr       Date:  2010

7.  Ductal carcinoma in situ of the breast: immune cell composition according to subtype.

Authors:  Marie Colombe Agahozo; Mieke R van Bockstal; Floris H Groenendijk; Thierry P P van den Bosch; Pieter J Westenend; Carolien H M van Deurzen
Journal:  Mod Pathol       Date:  2019-08-02       Impact factor: 7.842

8.  Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate.

Authors:  Andrew Rundle; Michelle Jankowski; Oleksandr N Kryvenko; Deliang Tang; Benjamin A Rybicki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-23       Impact factor: 4.254

9.  Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer.

Authors:  Feng Wang-Johanning; Ming Li; Francisco J Esteva; Kenneth R Hess; Bingnan Yin; Kiera Rycaj; Joshua B Plummer; Jeremy G Garza; Stefan Ambs; Gary L Johanning
Journal:  Int J Cancer       Date:  2013-09-13       Impact factor: 7.396

10.  Logical Differential Prediction Bayes Net, improving breast cancer diagnosis for older women.

Authors:  Houssam Nassif; Yirong Wu; David Page; Elizabeth Burnside
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.